Search Results for “EC” – Page 285 – media

Researchers reveal two different subtypes of prostate cancer using AI

In the UK alone, the aggressive form of cancer affects around 52,000 men every year Researchers from the University of Oxford and the University of Manchester have revealed that prostate cancer is not just a single disease and is made up of two different evotypes – subtypes of the disease. Published in Cell Genomics, the study, funded by Cancer Research UK and Prostate Cancer Research, used artificial intelligence (AI) to reveal a new form of aggressive prostate cancer. Currently the most common cancer affecting men in the UK, prostate cancer is responsible for around 52,000 cases every year. As part of the Pan Prostate Cancer Group; an international consortium set up by the Institute of Cancer Research (ICR) and the University of East Anglia (UEA), researchers applied AI to analyse the genetic data of 159 prostate cancer patient samples across nine countries. Using whole genome sequencing to study changes in ...
- Source: drugdu
- 127
- March 6, 2024
【EXPERT Q&A】How to distinguish a class, Class II, Class III medical devices?

Drugdu.com expert’s response: Medical devices are typically classified into different categories, including Class I, Class II, and Class III, based on their level of risk and intended use. Here is a general overview of how these categories are distinguished: Class I Medical Devices: Class I medical devices are generally considered to have low risk and may have little or no impact on the human body. They typically do not require specialized regulatory controls.These devices include simple, non-invasive devices such as thermometers, disposable gloves, non-invasive blood pressure monitors, etc. Class II Medical Devices: Class II medical devices pose higher risks compared to Class I devices and may have a moderate impact on the human body, requiring stricter regulatory controls.Examples of Class II devices include diagnostic equipment, infusion pumps, medical imaging devices, implantable medical devices, etc. Class III Medical Devices: Class III medical devices carry the highest level of risk and may cause ...
- Source: drugdu
- 156
- March 5, 2024
Interphex —NewYork biopharmaceutical Exhibition

Organiser: American pharmaceutical association Time:16 – 18 April 2024 address：655 West 34th Street New York, NY 10001-1188 USA Exhibition hall: Javits Convention Center, NYC Product range: Analytical instruments, automation and process control, batch processing systems/equipment, biological process equipment, packaging equipment, process equipment and parts, pilot plant equipment and custom components, tablet/capsule filling machine facility engineering and maintenance, environmental treatment and equipment, clean room equipment; Processing systems, control systems, automation instruments, pharmaceutical packaging materials, containers, etc About Interphex： The New York Biopharmaceutical Exhibition (Interphex) is one of the largest pharmaceutical exhibitions in North America. Held since 1979, it is the most trusted life science show in North America across both chemical and biopharmaceutical fields. Exhibitors meet decision buyers from the world’s top pharmaceutical companies through the exhibition.
- Source: drugdu
- 184
- March 5, 2024
New POC Malaria Test 12 Times Faster Than Currently Available Laboratory-Based Tests

Malaria continues to pose a major global health threat, with approximately 247 million cases and over 600,000 deaths annually, predominantly in sub-Saharan Africa. Particularly alarming is cerebral malaria, a severe form of the disease, which has a high mortality rate, especially among children under five. The existing rapid diagnostic tests (RDTs) for malaria offer a basic positive or negative result, but often fail to detect asymptomatic infections and lack the sensitivity required for early detection of severe cases. More sensitive molecular assays that exist are costly, time-consuming, and need specialized skills and equipment, rendering them unsuitable for widespread application in areas with limited resources. In light of these challenges, researchers have now developed a new test for diagnosing malaria that is both rapid and accurate. This POC rapid malaria test offers a significant improvement over traditional tests and will be especially beneficial for rural areas with limited healthcare facilities. Researchers ...
- Source: drugdu
- 97
- March 5, 2024
New Discoveries of Prostate Cancer Evolution Pave Way for Genetic Test

Prostate cancer ranks as one of the most common cancers affecting men, and while it accounts for a significant number of male cancer fatalities, many men live with it rather than die from it. Understanding when to avoid unnecessary treatments is crucial, as it can prevent side effects like incontinence and impotence. Now, new research has identified two distinct subtypes of prostate cancer, referred to as evotypes. This discovery could lead to major advancements in the diagnosis and treatment of prostate cancer. This discovery was made by an international consortium, called The Pan Prostate Cancer Group, which involved researchers from the University of Oxford (Oxford, UK), who used artificial intelligence (AI) to make new discoveries about the evolution of prostate cancer. Cancer development, like human evolution, can be traced and studied through its evolutionary history. By examining the cancer’s evolutionary tree, valuable insights about the disease can be gained, potentially ...
- Source: drugdu
- 163
- March 5, 2024
Biotheus’s PD-L1/VEGF dual antibody is planned to be included in breakthrough therapeutic category and has reached a licensing cooperation of over US$1 billion

Today (1st March), the official website of the Center for Drug Evaluation (CDE) of the NMPA announced that the PM8002 injection applied by Biotheus is planned to be included in the breakthrough therapy category, and the indication is the first-line treatment of inoperable locally advanced/recurrent metastatic triple-negative breast cancer with albumin-bound paclitaxel for combined injection. Public information shows that PM8002 is an anti-PD-L1/VEGF bispecific antibody independently developed by Biotheus. BioNTech has reached a cooperation agreement of more than US$1 billion with Biotheus to obtain the development, production and commercialization rights of this product worldwide (except Greater China). PM8002 is a bispecific antibody drug candidate consisting of a humanized anti-PD-L1 mono-antibody (VHH) fused to an anti-VEGF-A IgG1 antibody containing an Fc-silent mutation. This design can enrich PM8002 molecules into the tumor environment and reduce the systemic side effects caused by systemic VEGF blockade. According to an earlier press release fromBiotheus, PM8002 ...
- Source: drugdu
- 120
- March 5, 2024
WuXi Biologics’ Irish Site Awarded Three Authoritative ISO International Standard System Certifications

Dundalk, Ireland, March 1, 2024 – WuXi Biologics (2269.HK), a leading global contract research, development and manufacturing (CRDMO) services company, announced that its Dundalk, Ireland site has recently been awarded three authoritative ISO (International Organization for Standardization) accreditations at the same time, including ISO 50001 Energy Management System, ISO 14001 Environmental Management System and ISO 45001 Occupational Health and Safety Management System. ISO 50001 Energy Management System Certification, ISO 14001 Environmental Management System Certification and ISO 45001 Occupational Health and Safety Management System Certification, fully demonstrating that WuXi Biologics has always been adhering to the ESG (Environmental, Social and Governance) development strategy, and has consistently adhered to international standards and achieved outstanding results in environmental protection, sustainable energy development and employee health and safety. As a model for WuXi Biologics’ future factory, the Ireland site has been actively optimizing energy use, improving efficiency and reducing waste emissions from operations, and ...
- Source: drugdu
- 79
- March 5, 2024
Researchers reveal COVID-19 could have small impacts on cognition and memory

Different factors, such as illness duration and virus variant, impacted patients cognitive abilities Imperial College London (ICL) researchers have revealed that people who have recovered from COVID-19 could have small but long-lasting impacts on the performance of cognitive and memory tasks. Published in the New England Journal of Medicine, the REACT Long COVID study enrolled over 140,000 participants, including long COVID patients, who undertook at least one cognitive task. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. For some patients, the condition can lead to long COVID, where symptoms can last up to 12 weeks. Using an innovative online cognitive assessment via the Cognitron platform, researchers detected subtle changes in different areas of brain function, including memory, reasoning, executive function, attention and impulsivity. The study revealed small deficits that were still detectable after a year or more following infection, including in people who had a short duration of ...
- Source: drugdu
- 92
- March 5, 2024
ICL uses AI to help doctors assess lung cancer from ‘virtual biopsies’

TMR-CT will help doctors select treatment and predict the spread of lung cancer in patients Imperial College London (ICL) researchers have used artificial intelligence (AI) to identify information about the chemical makeup of lung tumours from medical scans of lung cancer. Published in npj Precision Oncology, the study demonstrates, for the first time, how medical imaging in combination with AI can be used to provide ‘virtual biopsies’ for cancer patients. Responsible for around 35,000 deaths each year, lung cancer is the most common cause of cancer death in the UK. Supported with funding from the National Institute for Health and Care Research’s Imperial Biomedical Research Centre, the non-invasive method works to classify the type of lung cancer patients have. Researchers used data from 48 lung cancer patients recruited from University Hospital Reina Sofia in Spain to develop an AI-powered, deep learning assessment tool called tissue-metabolomic-radiomic-CT (TMR-CT). Using the data, researchers ...
- Source: drugdu
- 66
- March 5, 2024
Pfizer’s Bivalent Respiratory Syncytial Virus Vaccine Shows Promising Efficacy Across Two Seasons

Davy James Abrysvo was found to produce durable efficacy against respiratory syncytial virus across two seasons in adults 60 years of age and older. Top-line data from the ongoing, pivotal Phase III RENOIR clinical trial (NCT05035212) demonstrated that Pfizer’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine Abrysvo produces durable efficacy against respiratory syncytial virus (RSV) across two seasons in adults 60 years of age and older. Efficacy against RSV-associated lower respiratory tract disease (LRTD), defined as three or more symptoms, was 88.9% after the first season, whereas efficacy was 77.8% after the second season.1 “We are encouraged by the level of protection that we observed after two full RSV seasons for Abrysvo,” Annaliesa Anderson, PhD, Pfizer senior vice president and chief scientific officer, Vaccine Research and Development, said in a press release. “This new data indicate that broad and durable protection against both types of RSV that cause ...
- Source: drugdu
- 152
- March 4, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.